

ONDANSETRON (Zofran)**Classification:** Anti-emetic**Actions:** Selective antagonism of the serotonin 5-HT₃ receptor
Decreases or eliminates nausea
Decreases/prevents episodes of vomiting**Indications:** Intractable vomiting or severe nausea for patients greater than 34 kg**Contraindications:**

1. Children < 34 kg base physician order only
2. Pregnancy – base physician order only
3. Hypersensitivity to 5-HT₃ receptor antagonists (i.e. Dolasetron (Anzemet), Granisetron (Kytril) or Palonosetron (Aloxi))
3. History of previous hypersensitivity to Zofran
4. Patients taking Apomorphine – (an injectable drug for Parkinson's Disease or rarely for erectile dysfunction – Apokyn, Spontane, Uprima)
5. Do not administer orally to those with known sensitivity to Phenylketonurics (contains phenylalanine)

Adverse Effects (Precautions, Side Effects and Notes):

Hypotension	Dizziness	Syncope
QT prolongation	Dysrhythmias	Flushing
Drowsiness	Rash	Anaphylaxis
Urinary Retention	Diarrhea	Headache

Ondansetron may cause QT prolongation in dose dependent manner, consider EKG monitoring or withholding in patients with long QT or at risk. Patients that do not respond to initial dose often do not respond to subsequent doses.

Administration:**ADULT DOSE**

4mg SLOW IV push over 1min - (rapid administration may result in syncope)
4mg IM or PO (oral disintegrating tablet - ODT)
May repeat PO every 20 min to a total of 12 mg

PEDIATRIC DOSE <34 kg – base physician order only

4 mg SLOW IV push over 1 min - (rapid administration may result in syncope)
4 mg IM or PO (oral disintegrating tablet - ODT)
Repeat per base physician order

Onset:

Route	Onset	Peak	Duration
P.O., I.V.	Rapid	15-30 min	4-8 hr
I.M.	Rapid	40 min	Unknown

Duration: 4-8 hours